Brought to you by 
Zogenix gets option on Altus’ abuse-deterrent form of Zohydro; business transferred to Pernix
03 Feb 2023
Executive Summary
As part of its efforts to prevent misuse and abuse of its newly approved severe chronic pain drug Zohydro (extended-release hydrocodone), neurological drug company Zogenix Inc. and Altus Formulation Inc. (delivery technology) started developing abuse-deterrent tablet versions of Zohydro incorporating Altus’ Intellitab technology. Zogenix holds an exclusive option to license US rights to further develop and sell these formulations.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Zogenix gets option on Altus’ abuse-deterrent form of Zohydro; business transferred to Pernix
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice